Alyeska Investment Group
JNCE

Alyeska Investment Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Alyeska Investment Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-262,105
Closed -$3.34M – 532
2017
Q4 		$3.34M Hold
262,105
– – 0.03% 284
2017
Q3 		$4.08M Buy
262,105
+79,683
+44% +$1.13M 0.03% 305
2017
Q2 		$2.56M Buy
182,422
+44,866
+33% +$960K 0.02% 328
2017
Q1 		$3.02M Buy
+137,556
New +$2.91M 0.02% 362

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group's JNCE Position: Q1 2018 in Review

Alyeska Investment Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2018, closing a stake of 262,105 shares — an estimated $3.34M sold.

Alyeska Investment Group first reported a position in JNCE in Q1 2017 and held it in 4 quarters. The position peaked at $4.08M in Q3 2017. 94 funds tracked by Wall St. Rank hold JNCE as of Q1 2018.

  • Alyeska Investment Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 262,105 Jounce Therapeutics, Inc. Common Stock shares in Q1 2018, an estimated $3.34M.
  • Alyeska Investment Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 4 quarters.
  • Alyeska Investment Group's Jounce Therapeutics, Inc. Common Stock position peaked at $4.08M in Q3 2017.
  • 94 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2018.

Based on Alyeska Investment Group's 13F filing for Q1 2018, filed 15 May 2018.